Novel acetamidothiazole derivatives: Synthesis and in vitro anticancer evaluation

European Journal of Medicinal Chemistry

Volumn 69, Issue , 2013, Pages 908-919

  Ali, Ahmed R ^a   El Bendary, Eman R ^a   Ghaly, Mariam A ^a   Shehata, Ihsan A ^a  

^a University of Mansoura   (Egypt)

Author keywords

Acetamidomorpholine; Acetamidopiperazine; Aminothiazole; Anticancer evaluation

Indexed keywords

1 (4 ACETYLPIPERAZIN 1 YL) 2 (2 IMINO 4 4 TOLYLTHIAZOL 3(2H) YL)ETHANONE; 1 (4 ACETYLPIPERAZIN 1 YL) 2 (2 IMINO 4 PHENYLTHIAZOL 3(2H) YL)ETHANONE; 1 (4 ACETYLPIPERAZIN 1 YL) 2 [4 (4 CHLOROPHENYL) 2 IMINOTHIAZOL 3(2H) YL]ETHANONE; 2 (2 IMINO 4 4 TOLYLTHIAZOL 3(2H) YL) 1 (4 PHENYLPIPERAZIN 1 YL)ETHANONE; 2 (2 IMINO 4 4 TOLYLTHIAZOL 3(2H) YL] 1 (4 METHYLPIPERAZIN 1 YL)ETHANONE; 2 (2 IMINO 4 4 TOLYLTHIAZOL 3(2H) YL] 1 MORPHOLINOETHANONE; 2 (2 IMINO 4 PHENYLTHIAZOL 3(2H) YL) 1 (4 METHYLPIPERAZIN 1 YL)ETHANONE; 2 (2 IMINO 4 PHENYLTHIAZOL 3(2H) YL) 1 (4 PHENYLPIPERAZIN 1 YL)ETHANONE; 2 (2 IMINO 4 PHENYLTHIAZOL 3(2H) YL) 1 MORPHOLINOETHANONE; 2 [4 (4 CHLOROPHENYL) 2 IMINOTHIAZOL 3(2H) YL] 1 (4 METHYLPIPERAZIN 1 YL)ETHANONE; 2 [4 (4 CHLOROPHENYL) 2 IMINOTHIAZOL 3(2H) YL] 1 (4 PHENYLPIPERAZIN 1 YL)ETHANONE; 2 [4 (4 CHLOROPHENYL) 2 IMINOTHIAZOL 3(2H) YL] 1 MORPHOLINOETHANONE; ACETAMIDE DERIVATIVE; ANTINEOPLASTIC AGENT; MORPHOLINE DERIVATIVE; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; MOLECULAR DOCKING; MOLECULAR WEIGHT; PHARMACOPHORE; PROTON NUCLEAR MAGNETIC RESONANCE; RING OPENING; ROOM TEMPERATURE;

ACETAMIDOMORPHOLINE; ACETAMIDOPIPERAZINE; AMINOTHIAZOLE; ANTICANCER EVALUATION; ARLHWYFAPHJCJT-UHFFFAOYSA-N; AXKCLMARXPEYOI-UHFFFAOYSA-N; BPAPVVZKFSFVIH-UHFFFAOYSA-N; DWGWNNCHJPKZNC-UHFFFAOYSA-N; FFEHZWWAKZFKGK-UHFFFAOYSA-N; FLAYZKKEOIAALB-UHFFFAOYSA-N; IHOGKRIRHORAHV-UHFFFAOYSA-N; ISGVIWPJZIQAJO-UHFFFAOYSA-N; KRVGXFREOJHJAX-UHFFFAOYSA-N; LIGACIXOYTUXAW-UHFFFAOYSA-N; MXCHJXBXBFDTNS-UHFFFAOYSA-N; OZSGMUVOGHBQRB-UHFFFAOYSA-N; PIDHTUREIXPEFO-UHFFFAOYSA-N; PSIGTNFUAOZMOF-UHFFFAOYSA-N; PYSJLPAOBIGQPK-UHFFFAOYSA-N; QPNYSIWOKUFJDJ-UHFFFAOYSA-N; RQQMXJAICONEOE-UHFFFAOYSA-N; RVXLBYMWQICVBU-UHFFFAOYSA-N; UJTCLCSSFRMSEH-UHFFFAOYSA-N; XYYGTTPKVXBPPI-UHFFFAOYSA-N; ZIFWCHUSQIPOCD-UHFFFAOYSA-N;

ACETAMIDES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 84885348829     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.08.021     Document Type: Article

References (91)

1. P.M. Bonilla, A.P. Cardena, E.Q. Marmol, J.L.A. Tellez, and G.J.M. Rejon Preparation, antimicrobial activity and toxicity of 2-amino-4-arylthiazole derivatives Heteroatom Chem. 17 2006 254 260
2. K.A. Parmar, B.G. Suthar, and S. Parajapati Synthesis and antibacterial evaluation of some novel 2-arylamino-4-phenyl-thiazolyl derivatives Bull. Korean Chem. Soc. 31 2010 793 797
3. A.K. Prajapati, and V.P. Modi Synthesis and biological evaluation of some substituted aminothiazole derivatives J. Chil. Chem. Soc. 55 2010 240 243
4. S.M. Basavarajaiah, and B.H.M. Mruthyunjayaswamy Synthesis and anti-microbial activity of (Z)-4-(4-substituted-thiazol-2-yl)-1-(2-oxoindolin-3- ylidene) semicarbazide and its derivatives Indian J. Chem. 49B 2010 1117 1126
5. A. Idhayadhulla, R.S. Kumar, and A.J.A. Nasser Synthesis, characterization and antimicrobial activity of new pyrrole derivatives J. Mex. Chem. Soc. 55 2011 218 223
6. P.J. Sanfilippo, M.C. Jetter, R. Cordova, R.A. Noe, E. Chourmouzis, C.Y. Lau, and E. Wangt Novel thiazole based heterocycles as inhibitors of LFA-l/ICAM-1 mediated cell adhesion J. Med. Chem. 38 1995 1057 1059
7. G. Saravanan, V. Alagarsamy, C.R. Prakash, P.D. Kumar, and T.P. Selvam Synthesis of novel thiazole derivatives as analgesic agents Asian J. Res. Pharm. Sci. 1 2011 134 138
8. N. Siddiqui, and W. Ahsan Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening Eur. J. Med. Chem. 45 2010 1536 1543
9. N. Siddiqui, and W. Ahsan Synthesis, anticonvulsant and toxicity screening of thiazolyl-thiadiazole derivatives Med. Chem. Res. 20 2011 261 268
10. A. Geronikaki, D.H. Litina, C. Chatziopoulos, and G. Soloupis Synthesis and biological evaluation of new 4,5-disubstituted thiazolyl amides, derivatives of 4-hydroxypiperidine or of 4-N-methyl piperazine Molecules 8 2003 472 479 (Pubitemid 38999145)
11. S.N. Mokale, P.T. Sanap, and D.B. Shinde Synthesis and hypolipidemic activity of novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy) acetic acid derivatives Eur. J. Med. Chem. 45 2010 3096 3100
12. P. Vicini, A. Geronikaki, M. Incerti, B. Busonera, G. Poni, C.A. Cabras, and P.L. Colla Synthesis and biological evaluation of benzo[d]isothiazole, benzothiazole and thiazole Schiff bases Bioorg. Med. Chem. 11 2003 4785 4789 (Pubitemid 37230135)
13. W. Fathalla Syntheses and reactions of methyl [3-(4-phenyl-thiazol-2-yl)- thioureido] alkanoates and related compounds ARKIVOC 12 2008 245 255
14. 3 receptor antagonists using FA and GFA techniques Bioorg. Med. Chem. 13 2005 1159 1165 (Pubitemid 40164600)
15. 1 receptor antagonists Bioorg. Med. Chem. 18 2010 2195 2203
16. K. Yamaguchi, M. Yada, T. Tsuji, Y. Hatanaka, K.I. Goda, and T. Kobori 4-phenylthiazole derivatives inhibit IL-6 secretion in osteoblastic cells and suppress the bone weight loss in the ovariectomized mice Bioorg. Med. Chem. Lett. 9 1999 957 960 (Pubitemid 29179888)
17. A.A. Geronikaki, J.C. Dearden, D. Filimonov, I. Galaeva, T.L. Garibova, T. Gloriozova, V. Krajneva, A. Lagunin, F.Z. Macaev, G. Molodavkin, V.V. Poroikov, S.I. Pogrebnoi, F. Shepeli, T.A. Voronina, M. Tsitlakidou, and L. Vlad Design of new cognition enhancers: from computer prediction to synthesis and biological evaluation J. Med. Chem. 47 2004 2870 2876 (Pubitemid 38656740)
18. Y. Laras, G. Quelever, C. Garino, N. Pietrancosta, M. Sheha, F. Bihel, M.S. Wolfec, and J.L. Kraus Substituted thiazolamide coupled to a redox delivery system: a new γ-secretase inhibitor with enhanced pharmacokinetic profile Org. Biomol. Chem. 3 2005 612 618 (Pubitemid 40296614)
19. I. Lagoja, C. Pannecouque, G. Griffioen, S. Wera, V.M. Rojasdelaparra, and A.V. Aerschot Substituted 2-aminothiazoles are exceptional inhibitors of neuronal degeneration in tau-driven models of Alzheimer's disease Eur. J. Pharm. Sci. 43 2011 386 392
20. R.H. Blum, S.K. Carter, and K. agre A clinical review of bleomycin-a new antineoplastic agent Cancer 31 1973 903 914
21. R.H. Advani, H.I. Hurwitz, M.S. Gordon, S.W. Ebbinghaus, D.S. Mendelson, H.A. Wakelee, U. Hoch, J.A. Silverman, N.A. Havrilla, C.J. Berman, J.A. Fox, R.S. Allen, and D.C. Adelman Voreloxin, a first-in-class anticancer quinolone derivative in relapsed/refractory solid tumors: a report on two dosing schedules Clin. Cancer Res. 16 2010 2167 2175
22. S. Goodin, M. Kane, and E. Rubin Epothilones: mechanism of action and biologic activity J. Clin. Oncol. 22 2004 2015 2025 (Pubitemid 41095195)
23. S. Stachel, K. Biswas, and S. Danishefsky The epothilones, eleutherobins and related types of molecules Curr. Pharm. Des. 7 2001 1277 1290 (Pubitemid 32798809)
24. M. Steinberg Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia Clin. Ther. 29 2007 2289 2308
25. M. Lindauer, and A. Hochhaus Dasatinib Recent Results Cancer Res. 184 2010 83 102
26. S. Shayani Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events Ther. Drug Monit. 32 2010 680 687
27. E.L. Luzina, and A.V. Popov Synthesis and anticancer activity of N-bis(trifluoromethyl)alkyl-N′-thiazolyl and N-bis(trifluoromethyl)alkyl- N′-benzothiazolyl ureas Eur. J. Med. Chem. 44 2009 4944 4953
28. R.N. Misra, H.Y. Xiao, D.K. Williams, K.S. Kim, S. Lu, K.A. Keller, J.G. Mulheron, R. Batorsky, J.S. Tokarski, J.S. Sack, S.D. Kimball, F.Y. Lee, and K.R. Webster Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases Bioorg. Med. Chem. Lett. 14 2004 2973 2977 (Pubitemid 38578421)
29. N.M. Raghavendra, S. Renuka, S.D. Gupta, and P. Divya Thiazole containing nitrogen mustards: synthesis, structural evaluation, cytotoxicity and DNA binding studies Lett. Drug Des. Discov. 8 2011 838 842
30. J. Kim, Y. Moon, and S.W. Ham 2-Aminothiazole derivative as a new class of TrkA kinase inhibitor Bull. Korean Chem. Soc. 32 2011 2893 2894
31. R. Romagnoli, P.G. Baraldi, M.D. Carrion, O.C. Lopez, C.L. Cara, G. Basso, G. Viola, M. Khedr, J. Balzarini, S. Mahboobi, A. Sellmer, A. Brancale, and E. Hamel 2-Arylamino-4-amino-5-aroylthiazoles. "One-pot" synthesis and biological evaluation of a new class of inhibitors of tubulin polymerization J. Med. Chem. 52 2009 5551 5555
32. B. Schiavi, A. Ahond, A. Al-Mourabit, C. Poupat, A. Chiaroni, C. Gaspard, and P. Potier Synthesis of 5-deazathiogirollines: analogs of a natural antitumor agent Tetrahedron 58 2002 4201 4215 (Pubitemid 34518687)
33. C.B. Yeh, C.J. Su, J.M. Hwang, and M.C. Chou Therapeutic effects of cantharidin analogues without bridging ether oxygen on human hepatocellular carcinoma cells Eur. J. Med. Chem. 45 2010 3981 3985
34. G.S. Hassan, S.M. El-Messery, F.A.M. Al-Omary, and H.I. El-Subbagh Substituted thiazoles VII. Synthesis and antitumor activity of certain 2-(substituted amino)-4-phenyl-1,3-thiazole analogs Bioorg. Med. Chem. Lett. 22 2012 6318 6323
35. I. Kayagil, and S. Demirayak Synthesis and anticancer activities of some thiazole derivatives Phosphorus Sulfur Silicon Relat. Elem. 184 2009 2197 2207
36. H.G. Garg, and R.A. Sharma Potential antineoplastics: 1-thiocarbamoyl-3-methyl-4-arylhydrazono-2-pyrazolin-5-one, 2-amino-4-phenyl-5- arylazothiazoles, and N-phenyl-N′-2 (4-phenyl-5-arylazothiazolyl) thiocarbamides J. Pharm. Sci. 59 1970 348 353
37. X. Zhou, L. Shao, Z. Jin, J.B. Liu, H. Dai, and J.X. Fang Synthesis and antitumor activity evaluation of some Schiff bases derived from 2-aminothiazole derivatives Heteroatom Chem. 18 2007 55 59 (Pubitemid 46225945)
38. H.I. El-Subbagh, A.H. Abadia, and J. Lehmann 2,4-Disubstituted thiazoles, part III 1: synthesis and antitumor activity of ethyl 2-substituted aminothiazole-4-carboxylate analogs Arch. Pharm. 332 1999 137 142 (Pubitemid 29190037)
39. A.A. El-Henawy Design, synthesis of new peptide derivatives and evaluated DNA binding activity, anticancer and antimicrobial activity J. Am. Sci. 6 11 2010 240 249
40. W. Liu, J. Zhou, F. Qi, K. Bensdorf, Z. Li, H. Zhang, H. Qian, W. Huang, X. Cai, P. Cao, A. Wellner, and R. Gust Synthesis and biological activities of 2-amino-thiazole-5-carboxylic acid phenylamide derivatives Arch. Pharm. 344 2011 451 458
41. K. Poreba, A. Opolski, and J. Wietrzyk Synthesis and antiproliferative activity in vitro of new 3-substituted aminopyrazolo[3,4-b]pyridines Acta Pol. Pharm. 59 2002 215 222
42. K. Poreba, J. Wietrzyk, and A. Opolski Synthesis and antiproliferative activity in vitro of new 3-substituted aminoisoxazolo[5,4-b]pyridines Acta Pol. Pharm. 60 2003 293 301 (Pubitemid 37279471)
43. S.N. Dighe, P.K. Chaskar, K.S. Jain, M.S. Phoujdar, and K.V. Srinivasan A remarkably high-speed solution-phase combinatorial synthesis of 2-substituted amino-4-arylthiazoles in polar solvents in the absence of a catalyst under ambient conditions and study of their antimicrobial activities ISRN Org. Chem. 2011 2011 1 6
44. A.T. Taher, H.H. Georgey, and H.I. El-Subbagh Novel 1,3,4-heterodiazole analogues: synthesis and in vitro antitumor activity Eur. J. Med. Chem. 47 2012 445 451
45. M.S.K. Youssef, R.A. Ahmed, M.S. Abbady, S.A. Abdel-Mohsen, and A.A. Omar Reactions of 4-(2-aminothiazole-4-yl)-3-methyl-5-oxo-1-phenyl-2-pyrazoline; synthesis of thiazolo[3,2-a]pyrimidine and imidazo[2,1-b]thiazole derivatives Monatsh. Chem. 139 2008 553 559
46. A.A. Kadi, H.A. El-Kashef, A.A.M. Abdel-Aziz, G.S. Hassan, J. Tettey, M.H. Grant, J. Lehmann, and H.I. El-Subbagh Synthesis, ultra-short acting hypnotic activity, and metabolic profile of ethyl 8-oxo-5,6,7,8-tetrahydro- thiazolo[3,2-a][1,3]diazepin-3-carboxylate (HIE-124) Arch. Pharm. 341 2008 81 89
47. M.F. El Shehry, A.A. Abu-Hashem, and E.M. El-Telbani Synthesis of 3-((2,4-dichlorophenoxy)methyl)-1,2,4-triazolo(thiadiazoles and thiadiazines) as anti-inflammatory and molluscicidal agents Eur. J. Med. Chem. 45 2010 1906 1911
48. H.R. Jaberi, and H. Noorizadeh Synthesis of some novel fused imidazo[2,1-b]1,3-thiazole and imidazo[2,1-b]thiazolo[5,4-d]isoxazole derivatives E-J. Chem. 9 2012 1518 1525
49. C.D. Hurd, and S. Hayao Reaction of propiolactone with heterocyclic amines J. Am. Chem. Soc. 77 1955 117 121
50. N. Swathi, T. Kumar, K. Haribabu, and C. Subrahmanyam Synthesis and biological evaluation of substituted thiazolamines, imidazo[2,1-b]thiazol-6-(5H) -ones, thiazolo[3,2-a]pyrimidin-5-ones and thiazolyl thioureas Indian J. Heterocycl. Chem. 21 2012 263 268
51. A.T. Mavrova, K.K. Anichina, D.I. Vuchev, J.A. Tsenov, P.S. Denkova, M.S. Kondeva, and M.K. Micheva Antihelminthic activity of some newly synthesized 5(6)-(un)substituted-1H-benzimidazol-2-ylthioacetylpiperazine derivatives Eur. J. Med. Chem. 41 2006 1412 1420 (Pubitemid 44883392)
52. NCI web site, www.dtp.nci.nih.gov.
53. M.R. Grever, S.A. Schepartz, and B.A. Chabner The national cancer institute cancer drug discovery and development program Semin.Oncol. 19 1992 622 638 (Pubitemid 23004840)
54. A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. Cronise, and A.V. Wolff Feasibility of a high flux anticancer drug screen utilizing a derive panel of human tumor cell lines in culture J. Natl. Cancer Inst. 83 1991 757 766
55. M.R. Boyd, and K.D. Paull Some practical consideration and applications of the national cancer institute in vitro anticancer drug discovery screen Drug Dev. Res. 34 1995 91 109
56. http://dtp.nci.nih.gov/docs/compare/compare.html.
57. K.D. Paull, R.H. Shoemaker, L. Hodes, A. Monks, D.A. Scudiero, L. Rubinstein, J. Plowman, and M.R. Boyd Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm J. Natl. Cancer Inst. 81 1989 1088 1092 (Pubitemid 19175145)
58. D.W. Zaharevitz, S.L. Holbeck, C. Bowerman, and P.A. Svetlik COMPARE: a web accessible tool for investigating mechanisms of cell growth inhibition J. Mol. Graphics Modell. 20 2002 297 303 (Pubitemid 34017547)
59. Y.Y. Zaytseva, J.D. Valentino, P. Gulhati, and B.M. Evers mTOR inhibitors in cancer therapy Cancer Lett. 319 2012 1 7
60. C.K. Tsang, H. Qi, L.F. Liu, and X.F.S. Zheng Targeting mammalian target of rapamycin (mTOR) for health and diseases Drug Discov. Today 12 2007 112 124 (Pubitemid 46176669)
61. R.A. Kirken, and Y.L. Wang Molecular actions of sirolimus: sirolimus and mTOR Transplant. Proc. 35 2003 227 230
62. T.D. Brown, D.S. Ettinger, and R.C. Donehower A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer J. Clin. Oncol. 4 1986 1270 1276 (Pubitemid 16043879)
63. E.K. Rowinsky, D.S. Ettinger, W.P. McGuire, D.A. Noe, L.B. Grochow, and R.C. Donehower Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study Cancer Res. 47 1987 5788 5795 (Pubitemid 18046782)
64. M.C. Bibby Flavone acetic acid - an interesting novel therapeutic agent or just another disappointment? Br. J. Cancer 63 1991 3 5
65. C.A. Lipinski, F. Lombardo, and B.W. Dominy Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3 25 (Pubitemid 27046991)
66. Canvas, Version 1.2 2009 Schrödinger, LLC New York, NY
67. http://www.organic-chemistry.org/prog/peo.
68. D.E. Clark, and S.D. Pickett Computational methods for the prediction of 'drug-likeness' Drug Discov. Today 5 2000 49 58
69. J.L. Jenkins, A. Bender, and J.W. Davies In silico target fishing: predicting biological targets from chemical structure Drug Discov. Today Technol. 3 2006 413 421 (Pubitemid 46158395)
70. X. Liu, S. Ouyang, B. Yu, K. Huang, Y. Liu, J. Gong, S. Zheng, Z. Li, H. Li, and H. Jiang PharmMapper server: a web server for potential drug target identification via pharmacophore mapping approach Nucleic Acids Res. 38 2010 609 614
71. 3 substitutions Bioorg. Med. Chem. Lett. 14 2004 4897 4902 (Pubitemid 39165590)
72. D. Santinia, S. Galluzzoa, A. Zoccolia, F. Pantanoa, M.E. Frattoa, B. Vincenzia, L. Lombardib, C. Gucciardinoa, N. Silvestrisc, E. Rivad, S. Rizzoe, A. Russoe, E. Maiellob, G. Coluccic, and G. Toninia New molecular targets in bone metastases Cancer Treat. Rev. 36 2010 6 10
73. S.K. Thompson, S.M. Halbert, M.J. Bossard, T.A. Tomaszek, M.A. Levy, B. Zhao, W.W. Smith, S.S. Abdel-Meguid, C.A. Janson, K.J. D'Alessio, M.S. Mcqueney, B.Y. Amegadzie, C.R. Hanning, R.L. Dejarlais, J. Briand, S.K. Sarkar, M.J. Huddleston, C.F. Ijames, S.A. Carr, K.T. Garnes, A. Shu, J.R. Heys, J. Bradbeer, D. Zembryki, L.L. Rykaczewski, I.E. James, M.W. Lark, F.H. Drake, M. Gowen, J.G. Gleason, and D.F. Vener Design of potent and selective human cathepsin K inhibitors that span the active site Proc. Natl. Acad. Sci. U. S. A. 94 1997 14249 14254 (Pubitemid 28041359)
74. K.K. Deeb, D.L. Trump, and C.S. Johnson Vitamin D signalling pathways in cancer: potential for anticancer therapeutics Nat. Rev. Cancer 7 2007 684 700 (Pubitemid 47327412)
75. C. Carlberg, and F. Molnár Current status of vitamin D signaling and its therapeutic applications Curr. Top. Med. Chem. 12 2012 528 547
76. A.L. Jackman, and A.H. Calvert Folate-based thymidylate synthase inhibitors as anticancer drugs Ann. Oncol. 6 1995 871 881
77. A. Gangjee, H.D. Jaina, and R.L. Kisliuk Novel 2-amino-4-oxo-5-arylthio- substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolate inhibitors of thymidylate synthase Bioorg. Med. Chem. Lett. 15 2005 2225 2230 (Pubitemid 40523077)
78. A. Gangjee, J. Yang, J.J. McGuireb, and R.L. Kisliukc Synthesis and evaluation of a classical 2,4-diamino-5-substituted furo[2,3-d]pyrimidine and a 2-amino-4-oxo-6-substituted pyrrolo[2,3-d]pyrimidine as antifolates Bioorg. Med. Chem. 14 2006 8590 8598 (Pubitemid 44667525)
79. 4 hydrolase inhibitors using metabolomics biased fragment crystallography J. Med. Chem. 52 2009 4694 4715
80. 4 hydrolase inhibitors based on piperidine and piperazine scaffolds Bioorg. Med. Chem. Lett. 20 2010 2851 2854
81. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934 (Pubitemid 35425239)
82. S. Daouti, H. Wang, W. Li, B. Higgins, K. Kolinsky, K. Packman, A. Specian Jr., N. Kong, N. Huby, Y. Wen, Q. Xiang, F.J.P. dlaski, Y. He, N. Fotouhi, D. Heimbrook, and H. Niu Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy Cancer Res. 69 2009 1924 1932
83. R.A. Heald, P. Jackson, P. Savy, M. Jones, E. Gancia, B. Burton, R. Newman, J. Boggs, E. Chan, J. Chan, E. Choo, M. Merchant, P. Rudewicz, M. Ultsch, C. Wiesmann, Q. Yue, M. Belvin, and S. Price Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions J. Med. Chem. 55 2012 4594 4604
84. R. Roskoski Jr. Src protein-tyrosine kinase structure and regulation Biochem. Biophys. Res. Commun. 324 2004 1155 1164 (Pubitemid 40292143)
85. J.L. Buchanan, R.S. Bohacek, G.P. Luke, M. Hatada, X. Lu, D.C. Dalgamo, S.S. Narula, R. Yuan, and D.A. Holt Structure-based design and synthesis of a novel class of SRC SH2 inhibitor Bioorg. Med. Chem. Lett. 9 1999 2353 2358 (Pubitemid 29391521)
86. R. Thaimattam, P.R. Daga, R. Banerjeea, and J. Iqbal 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases Bioorg. Med. Chem. 13 2005 4704 4712 (Pubitemid 40848348)
87. I. Pevet, C. Brulé, A. Tizot, A. Gohier, F. Cruzalegui, J.A. Boutin, and S. Goldstein Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors Bioorg. Med. Chem. 19 2011 2517 2528
88. Y.M. Yin, Y.T. Geng, Y.F. Shao, X.L. Hu, W. Li, Y.Q. Shu, and Z.X. Wang First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer J. Exp. Clin. Cancer Res. 29 2010 126 132
89. C. Gridelli, F.D. Marinisb, M.D. Maioc, D. Cortinovisd, F. Cappuzzoe, and T. Mokf Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: review of the evidence Lung Cancer 71 2011 249 257
90. Z. Bikadi, S. Kovacs, L. Demko, and E. Hazai DockingServer 2007 Virtua Drug Ltd. Budapest, Hungary www.dockingserver.com
91. L. Yang, H. Luo, J. Chen, Q. Xing, and L. He SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome Nucleic Acids Res. 37 2009 406 412